MapLight Therapeutics registers 13.2 million shares for resale after $150 million private placementSep 9FinancingMapLight Therapeutics
MapLight enters $150M private placement agreement, reports Q2 2026 resultsAug 13Clinical readoutMapLight TherapeuticsML-007C-MA
MapLight's ML-007C-MA hits primary endpoint, company plans confirmatory pivotal trialJul 27Clinical readoutMapLight TherapeuticsML-007C-MA
Sign inSign in